{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=18",
    "query": {
      "intervention": "Biological Control",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 1573,
    "total_pages": 158,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T17:28:44.376Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01540474",
      "title": "Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Group 1: 10 ug FMP012 with 2 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Group 2: 10 ug FMP012 with 5 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Controlled group-Challenged Only: no vaccination",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-02",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01540474"
    },
    {
      "nct_id": "NCT00362440",
      "title": "Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Lipodystrophy"
      ],
      "interventions": [
        {
          "name": "Leptin",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone or metformin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2006-08",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-23",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362440"
    },
    {
      "nct_id": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML (Acute Myelogenous Leukemia)",
        "Acute Lymphoid Leukemia (ALL)",
        "Acute Leukemia (Category)",
        "MDS (Myelodysplastic Syndrome)",
        "CML (Chronic Myelogenous Leukemia)",
        "CLL (Chronic Lymphocytic Leukemia)",
        "Prolymphocyctic Leukemia",
        "Chronic Myelomonocytic Leukemia (CMML)",
        "Myeloproliferative Neoplasm (MPN)",
        "Lymphoma",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Conditioning Regimen A",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen B",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen C",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen D",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen E",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "PTCy (50 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "PTCy (25 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Growth Factors",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Blood Products",
          "type": "PROCEDURE"
        },
        {
          "name": "Supportive Care: Infection Prophylaxis",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Intravenous immune globulin (IVIG)",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Seizure prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Monitoring and management of CRS",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Lipid elevations",
          "type": "OTHER"
        },
        {
          "name": "Study treatment compliance",
          "type": "OTHER"
        },
        {
          "name": "Prohibited Concomitant Therapy",
          "type": "OTHER"
        },
        {
          "name": "Permitted Concomitant Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 358,
      "start_date": "2025-07-25",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06859424"
    },
    {
      "nct_id": "NCT06335797",
      "title": "Optimization of Postoperative Bowel Habits",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Constipation"
      ],
      "interventions": [
        {
          "name": "Senna Tab",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dulcolax Suppositories",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 88,
      "start_date": "2024-10-16",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06335797"
    },
    {
      "nct_id": "NCT06413095",
      "title": "PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MK-0482 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "MK-4830 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2022-06-01",
      "completion_date": "2023-06-22",
      "has_results": false,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06413095"
    },
    {
      "nct_id": "NCT05074277",
      "title": "Skeletal Response to Simulated Night Shift",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoporosis",
        "Circadian Rhythm Sleep Disorder, Shift Work Type"
      ],
      "interventions": [
        {
          "name": "Simulated short term night shift work schedule",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "20 Years to 40 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-02-08",
      "completion_date": "2025-12-18",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05074277"
    },
    {
      "nct_id": "NCT01064401",
      "title": "Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BIIB019 (Daclizumab High Yield Process)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interferon beta-1a Placebo",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta-1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Daclizumab High Yield Process Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1841,
      "start_date": "2010-05",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-07-11",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 46,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01064401"
    },
    {
      "nct_id": "NCT00001119",
      "title": "Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tetanus Toxoid Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Indinavir sulfate",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine/Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Abacavir sulfate",
          "type": "DRUG"
        },
        {
          "name": "Amprenavir",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        },
        {
          "name": "Hepatitis B Vaccine (Recombinant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 288,
      "start_date": "1999-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-03-02",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001119"
    },
    {
      "nct_id": "NCT02212457",
      "title": "Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infections, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Bexsero",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Placebo",
          "type": "OTHER"
        },
        {
          "name": "Havrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MenABCWY",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 1063,
      "start_date": "2014-08-21",
      "completion_date": "2016-03-03",
      "has_results": true,
      "last_update_posted_date": "2019-06-27",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 13,
      "location_summary": "Jonesboro, Arkansas • Hialeah, Florida • Melbourne, Florida + 10 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Kansas"
        },
        {
          "city": "Niles",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02212457"
    },
    {
      "nct_id": "NCT00005095",
      "title": "Specimen and Data Study for Ovarian Cancer Early Detection and Prevention",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cervical Cancer",
        "Endometrial Cancer",
        "Fallopian Tube Cancer",
        "Hereditary Breast/Ovarian Cancer (brca1, brca2)",
        "Ovarian Cancer",
        "Sarcoma",
        "Uterine Leiomyomata",
        "Vaginal Cancer",
        "Vulvar Cancer"
      ],
      "interventions": [
        {
          "name": "Ca-125",
          "type": "OTHER"
        },
        {
          "name": "screening questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 6000,
      "start_date": "2000-03",
      "completion_date": "2040-12",
      "has_results": false,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-10-23T17:28:44.376Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005095"
    }
  ]
}